Who owns Ambrolytin?
Ambrolytin is owned by Sopharma (Bulgaria, BSE Sofia: SFA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Key facts
- Current owner
- Sopharma AD reported
- Owned since
- Not recorded
- Previous owner
- None recorded
- Owner HQ
- 🇧🇬 Bulgaria, Sofia
- Origin
- 🇧🇬 Bulgaria
- Category
- Consumer health › Over-the-counter medicine › Cold
- Parent ticker
- BSE Sofia: SFA WSE: SPH
- Last verified
- · 1 sources
About Ambrolytin
Ambrolytin is Sopharma's ambroxol syrup, sold in Bulgaria at 30 mg per 5 ml, and its Bulgarian marketing authorisation was renewed in the first half of 2026 as one of nineteen the group renewed in the period. Sopharma makes liquid dosage forms at its plants in Vrabevo, Sandanski and Veliko Tarnovo, with capacity for about seventeen million packs a year.
Ownership timeline of Ambrolytin
Where Ambrolytin sits in Sopharma
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Sopharma ownership tree →
Other brands owned by Sopharma in consumer health
Latest news about Ambrolytin
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who is the parent company of Ambrolytin?
The parent company of Ambrolytin is Sopharma, a publicly listed company headquartered in Bulgaria.
Is Ambrolytin Bulgarian?
Yes. Ambrolytin originated in Bulgaria and its owner, Sopharma, is also headquartered in Bulgaria.
Is Ambrolytin still owned by Sopharma?
Yes. As of 20 September 2026, Ambrolytin is still owned by Sopharma. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Sopharma Group consolidated management report for the first half of 2026 — Sopharma AD, Stock exchange filing, published 30 June 2026; retrieved 20 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.